Functional characterization of novel germline TP53 variants in Swedish families

被引:10
|
作者
Kharaziha, Pedram [1 ]
Ceder, Sophia [1 ]
Axell, Olga [1 ]
Krall, Moritz [1 ]
Fotouhi, Omid [1 ]
Bohm, Stefanie [1 ]
Lain, Sonia [2 ]
Borg, Ake [3 ]
Larsson, Catharina [1 ]
Wiman, Klas G. [1 ]
Tham, Emma [4 ,5 ]
Bajalica-Lagercrantz, Svetlana [1 ,5 ]
机构
[1] Karolinska Univ Hosp, Karolinska Inst, Canc Ctr Karolinska, Dept Oncol Pathol, BioClinicum J6-20, SE-17176 Stockholm, Sweden
[2] Karolinska Inst, Dept Microbiol Tumor & Cell Biol, Stockholm, Sweden
[3] Lund Univ, Div Oncol Pathol, Lund, Sweden
[4] Karolinska Inst, Dept Mol Med & Surg, Stockholm, Sweden
[5] Karolinska Univ Hosp, Dept Clin Genet, Stockholm, Sweden
关键词
germline TP53 mutation; hereditary breast cancer; Li-Fraumeni syndrome; p53; activity; LI-FRAUMENI SYNDROME; ONSET BREAST-CANCER; MUTANT P53; MUTATION CARRIERS; IMAGING SURVEILLANCE; RISK; BINDING; BRCA2;
D O I
10.1111/cge.13564
中图分类号
Q3 [遗传学];
学科分类号
071007 ; 090102 ;
摘要
Pathogenic germline TP53 variants predispose to a wide range of early onset cancers, often recognized as the Li-Fraumeni syndrome (LFS). They are also identified in 1% of families with hereditary breast cancer (HrBC) that do not fulfill the criteria for LFS. In this study, we present a total of 24 different TP53 variants identified in 31 Swedish families with LFS or HrBC. Ten of these variants, nine exonic and one splice, have previously not been described as germline pathogenic variants. The nine exonic variants were functionally characterized and demonstrated partial transactivation activity compared to wild-type p53. Some show nuclear localization similar to wild-type p53 while others possess cytoplasmic or perinuclear localization. The four frameshift variants (W91Gfs*32, L111 Wfs*12, S227 Lfs*20 and S240Kfs*25) had negligible, while F134 L and T231del had low level of p53 activity. The L111 Wfs*12 and T231del variants are also deficient for induction of apoptosis. The missense variant R110C retain p53 effects and the nonsense E349* shows at least partial transcription factor activity but has reduced ability to trigger apoptosis. This is the first functional characterization of novel germline TP53 pathogenic or likely pathogenic variants in the Swedish cohort as an attempt to understand its association with LFS and HrBC, respectively.
引用
收藏
页码:216 / 225
页数:10
相关论文
共 50 条
  • [41] Genotype and phenotype in carriers of germline tp53 mutations
    Varley J.
    Evans G.
    Birch J.
    Kelsey A.
    Nature Genetics, 2001, 27 (Suppl 4) : 92 - 93
  • [42] Germline mutations of TP53 gene in breast cancer
    Damineni, Surekha
    Rao, Vadlamudi Raghavendra
    Kumar, Satish
    Ravuri, Rajasekar Reddy
    Kagitha, Sailaja
    Dunna, Nageswara Rao
    Digumarthi, Raghunadharao
    Satti, Vishnupriya
    TUMOR BIOLOGY, 2014, 35 (09) : 9219 - 9227
  • [43] Genotype and phenotype in carriers of germline TP53 mutations
    Varley, J
    Evans, DGR
    Kelsey, AM
    Birch, JM
    JOURNAL OF MEDICAL GENETICS, 2000, 37 : S22 - S22
  • [44] Germline mutations of TP53 and BRCA2 genes in breast cancer/sarcoma families
    Manoukian, Siranoush
    Peissel, Bernard
    Pensotti, Valeria
    Barile, Monica
    Cortesi, Laura
    Stacchiotti, Silvia
    Terenziani, Monica
    Barbera, Floriana
    Pasquini, Graziella
    Frigerio, Simona
    Pierotti, Marco A.
    Radice, Paolo
    Della-Torre, Gabriella
    EUROPEAN JOURNAL OF CANCER, 2007, 43 (03) : 601 - 606
  • [45] Gestational choriocarcinoma associated with a germline TP53 mutation
    Brehin, Anne-Claire
    Patrier-Sallebert, Sophie
    Bougeard, Gaelle
    Side-Pfennig, Gwendoline
    Gutierrez, Francisco Llamas
    Lamy, Aude
    Colasse, Elodie
    Kandel-Aznar, Christine
    Delnatte, Capucine
    Vuillemin, Eric
    Sadot-Lebouvier, Sophie
    Odent, Sylvie
    Sabourin, Jean-Christophe
    Golfier, Francois
    Frebourg, Thierry
    FAMILIAL CANCER, 2018, 17 (01) : 113 - 117
  • [46] Surveillance recommendations for patients with germline TP53 mutations
    Ballinger, Mandy L.
    Mitchell, Gillian
    Thomas, David M.
    CURRENT OPINION IN ONCOLOGY, 2015, 27 (04) : 332 - 337
  • [47] Germline mutation in the TP53 gene in uveal melanoma
    Nikola Hajkova
    Jan Hojny
    Kristyna Nemejcova
    Pavel Dundr
    Jan Ulrych
    Katerina Jirsova
    Johana Glezgova
    Ivana Ticha
    Scientific Reports, 8
  • [48] Germline mutation in the TP53 gene in uveal melanoma
    Hajkova, Nikola
    Hojny, Jan
    Nemejcova, Kristyna
    Dundr, Pavel
    Ulrych, Jan
    Jirsova, Katerina
    Glezgova, Johana
    Ticha, Ivana
    SCIENTIFIC REPORTS, 2018, 8
  • [49] Gestational choriocarcinoma associated with a germline TP53 mutation
    Anne-Claire Brehin
    Sophie Patrier-Sallebert
    Gaëlle Bougeard
    Gwendoline Side-Pfennig
    Francisco Llamas Gutierrez
    Aude Lamy
    Elodie Colasse
    Christine Kandel-Aznar
    Capucine Delnatte
    Eric Vuillemin
    Sophie Sadot-Lebouvier
    Sylvie Odent
    Jean-Christophe Sabourin
    François Golfier
    Thierry Frebourg
    Familial Cancer, 2018, 17 : 113 - 117
  • [50] Variable population prevalence estimates of germline TP53 variants: A gnomAD-based analysis
    de Andrade, Kelvin C.
    Frone, Megan N.
    Wegman-Ostrosky, Talia
    Khincha, Payal P.
    Kim, Jung
    Amadou, Amina
    Santiago, Karina M.
    Fortes, Fernanda P.
    Lemonnier, Nathanal
    Mirabello, Lisa
    Stewart, Douglas R.
    Hainaut, Pierre
    Kowalski, Luiz P.
    Savage, Sharon A.
    Achatz, Maria I.
    HUMAN MUTATION, 2019, 40 (01) : 97 - 105